TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36517745

Group type: EXPERIMENTAL
Intervention: D-SCOPE program (6-step detection and prevention program)
Number of subjects: 869
Study: 36517767

Group type: EXPERIMENTAL
Intervention: Erenumab (140 mg)
Number of subjects: 32
Study: 36517849

Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strategies to reduce stigma affecting PWH on MMT
Number of subjects: 31
Study: 36517856

Group type: EXPERIMENTAL
Intervention: Olipudase alfa enzyme replacement therapy
Number of subjects: 20
Study: 36517865

Group type: EXPERIMENTAL
Intervention: AV-GBM-1 vaccine administration
Number of subjects: 63
Study: 36517899

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure (BP) variability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative SBP difference > -5 mmHg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate analysis adjusted for age, sex, presence of diabetes, and 24-h ambulatory SBP
Number of subjects: 0
Study: 36517906

Group type: EXPERIMENTAL
Intervention: Machine learning-enabled real-time echocardiographic assessment of left ventricular ejection fraction (LVEF)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Manual measurements by experts
Number of subjects: 95
Study: 36517997

Group type: EXPERIMENTAL
Intervention: One-stage full-mouth scaling and root planing (FM-SRP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Quadrant-wise scaling and root planing (Q-SRP)
Number of subjects: 40
Study: 36518248

Group type: EXPERIMENTAL
Intervention: ctDNA-guided therapy
Number of subjects: 104
Study: 36518253

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor letrozole (2.5mg/day; n=11)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Intramuscular testosterone (1mg/kg/every 4 weeks; n=11)
Number of subjects: 22
Study: 36518364

Group type: EXPERIMENTAL
Intervention: SRS-2 total scores for girls
Number of subjects: 384

Group type: COMPARATOR
Intervention: SRS-2 total scores for boys
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Correlation between SRS-2 total score and IQ for girls
Number of subjects: 384
Study: 36518606

Group type: EXPERIMENTAL
Intervention: Tailored counseling and navigation (TCN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Targeted print brochure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36518723

Group type: EXPERIMENTAL
Intervention: Referral for SCD risk stratification and management
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Attendance at SCD risk stratification and management visit
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Meeting ICD indication criteria
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: ICD implantation
Number of subjects: 1491

Group type: EXPERIMENTAL
Intervention: Overall referral and ICD implantation rates
Number of subjects: 1491
Study: 36518729

Group type: EXPERIMENTAL
Intervention: Scheduled, simultaneous doses of acetaminophen, celecoxib, and pregabalin; oxycodone 5 mg as needed for breakthrough pain.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ibuprofen and oxycodone 5 mg/acetaminophen 325 mg as needed for pain (Control).
Number of subjects: 100
Study: 36518770

Group type: EXPERIMENTAL
Intervention: CNI weaning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36518987

Group type: EXPERIMENTAL
Intervention: Serum progesterone levels ≥7.8 ng/ml
Number of subjects: 402

Group type: COMPARATOR
Intervention: Serum progesterone levels <7.8 ng/ml
Number of subjects: 402
Study: 36519118

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Number of subjects: 5
Study: 36519188

Group type: EXPERIMENTAL
Intervention: Buprenorphine/Naloxone (BUP/NX)
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 272
Study: 36519287

Group type: EXPERIMENTAL
Intervention: 16-week concurrent exercise program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Counseling (control group)
Number of subjects: 150
Study: 36519326

Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis arm
Number of subjects: 152

Group type: COMPARATOR
Intervention: SOC arm
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Defibrotide prophylaxis arm (subgroup with antithymocyte globulin)
Number of subjects: 152

Group type: COMPARATOR
Intervention: SOC arm (subgroup with antithymocyte globulin)
Number of subjects: 152
Study: 36519325

Group type: EXPERIMENTAL
Intervention: Venetoclax-azacitidine
Number of subjects: 39
Study: 36519451

Group type: EXPERIMENTAL
Intervention: Intensive goal SBP <120 mm Hg
Number of subjects: 7860

Group type: COMPARATOR
Intervention: Standard goal SBP <140 mm Hg
Number of subjects: 7860
Study: 36519564

Group type: EXPERIMENTAL
Intervention: Use of speedometer during colonoscopy
Number of subjects: 166

Group type: COMPARATOR
Intervention: No speedometer during colonoscopy
Number of subjects: 166
Study: 36519620

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Early paracetamol treatment
Number of subjects: 2278

Group type: COMPARATOR
Intervention: Late paracetamol treatment
Number of subjects: 2278

Group type: EXPERIMENTAL
Intervention: Paracetamol combined with ibuprofen
Number of subjects: 2278
Study: 36519749

Group type: EXPERIMENTAL
Intervention: Maintenance nivolumab SOC (480 mg 4 weekly)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Extended interval (480 mg 8 weekly)
Number of subjects: 160
Study: 36519767

Group type: EXPERIMENTAL
Intervention: Family-centered care intervention for well-nourished participants
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group for well-nourished participants
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Family-centered care intervention for poorly-nourished participants
Number of subjects: 134

Group type: COMPARATOR
Intervention: Control group for poorly-nourished participants
Number of subjects: 134
Study: 36519982

Group type: EXPERIMENTAL
Intervention: Prone position during ECMO
Number of subjects: 517
Study: 36519984

Group type: EXPERIMENTAL
Intervention: astegolimab
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: efmarodocokin alfa
Number of subjects: 396

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 396
Study: 36520008

Group type: EXPERIMENTAL
Intervention: Lomitapide (median 5.1 years)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lomitapide (more than 9 years in 34 patients in Italy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lomitapide (phase 3 trial and LOWER registry)
Number of subjects: 0
Study: 36520162

Group type: EXPERIMENTAL
Intervention: 3 T-R2* LIC
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.5 T-R2* LIC
Number of subjects: 30
Study: 36520177

Group type: EXPERIMENTAL
Intervention: Drain
Number of subjects: 144

Group type: COMPARATOR
Intervention: No Drain
Number of subjects: 144
Study: 36520251

Group type: EXPERIMENTAL
Intervention: Phase-Advance Intervention (PAI): 1 night of late-night wake therapy (LWT: sleep 9 pm-1 am) followed by 7 days of morning bright white light (BWL)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Phase-Delay Intervention (PDI): 1 night of early-night wake therapy (EWT: sleep 3-7 am) plus 7 days of evening BWL
Number of subjects: 44
Study: 36520325

Group type: EXPERIMENTAL
Intervention: Tdap vaccine (Boostrix) administered on or after the 27th week of pregnancy
Number of subjects: 16350

Group type: COMPARATOR
Intervention: No Tdap vaccine during pregnancy (control group)
Number of subjects: 16350
Study: 36520426

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg plus Bevacizumab 15 mg/kg on day 1 of each 21-day cycle until disease progression or unacceptable toxic effects.
Number of subjects: 38
Study: 36520462

Group type: EXPERIMENTAL
Intervention: SB11 (0.5 mg)
Number of subjects: 705

Group type: COMPARATOR
Intervention: RBZ (0.5 mg)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: SB11
Number of subjects: 705
Study: 36520519

Group type: EXPERIMENTAL
Intervention: Tappt digital health system (RTM)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 123
Study: 36520613

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study: 36520715

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily for six additional weeks
Number of subjects: 402

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study: 36520813

Group type: EXPERIMENTAL
Intervention: Triclosan coated suture (TCS)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Non-coated suture VICRYL
Number of subjects: 380
Study: 36520927

Group type: EXPERIMENTAL
Intervention: Aggregate-level response screening format
Number of subjects: 367

Group type: COMPARATOR
Intervention: Item-level response screening format
Number of subjects: 367
Study: 36521030

Group type: EXPERIMENTAL
Intervention: Pola-DA-EPCH-R (vincristine omitted)
Number of subjects: 18
Study: 36521078

Group type: EXPERIMENTAL
Intervention: Adjuvant Exemestane with Ovarian Suppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36521097

Group type: EXPERIMENTAL
Intervention: Adjuvant treatment
Number of subjects: 866
Study: 36521100

Group type: EXPERIMENTAL
Intervention: Serious Illness Care Program (SICP) delivered via telehealth
Number of subjects: 45
Study: 36521103

Group type: EXPERIMENTAL
Intervention: SurVaxM plus adjuvant temozolomide (TMZ)
Number of subjects: 64
Study: 36521131

Group type: EXPERIMENTAL
Intervention: Integrative couple treatment for pathological gambling (ICT-PG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Individual treatment approach
Number of subjects: 80
Study: 36521262

Group type: EXPERIMENTAL
Intervention: Inhaled single-dose MK-5475 (120 μg and 360 μg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled single-dose MK-5475
Number of subjects: 0
Study: 36521330

Group type: EXPERIMENTAL
Intervention: Physical inactivity
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Feeling nervous
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Coronary artery disease
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Sleep disturbances
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Severe disease course
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Third pandemic wave
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Illness during the fourth wave
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Illness during the fifth wave
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 568
Study: 36521501

Group type: EXPERIMENTAL
Intervention: Pegozafermin 3 mg once weekly
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pegozafermin 9 mg once weekly
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pegozafermin 18 mg once weekly
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pegozafermin 27 mg once weekly
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pegozafermin 18 mg once every 2 weeks
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Pegozafermin 36 mg once every 2 weeks
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 36521580

Group type: EXPERIMENTAL
Intervention: Hydrodilatation with 40 mg triamcinolone acetonide (TA)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Hydrodilatation with 10 mg triamcinolone acetonide (TA)
Number of subjects: 84
Study: 36521694

Group type: EXPERIMENTAL
Intervention: Theta-beta ratio neurofeedback (NF)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control treatment (identical appearance, intensity/frequency, and duration)
Number of subjects: 142
Study: 36521802

Group type: EXPERIMENTAL
Intervention: Early introduction of peanut products at 4 months for infants with eczema
Number of subjects: 2137

Group type: EXPERIMENTAL
Intervention: Early introduction of peanut products at 6 months for infants without eczema
Number of subjects: 2137

Group type: EXPERIMENTAL
Intervention: Delayed introduction of peanut products to 12 months
Number of subjects: 2137

Group type: EXPERIMENTAL
Intervention: Targeting only the highest-risk infants with severe eczema
Number of subjects: 2137
Study: 36521878

Group type: EXPERIMENTAL
Intervention: Sudoscan
Number of subjects: 2243

Group type: COMPARATOR
Intervention: Monofilament test
Number of subjects: 2243

Group type: COMPARATOR
Intervention: Tuning fork test
Number of subjects: 2243

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 2243
Study: 36521884

Group type: EXPERIMENTAL
Intervention: MRI parameters (T2-weighted and diffusion tensor images)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Neck Disability Index and self-rated global recovery question
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing and skin biopsies
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Regression analysis
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Linear and logistic regression analyses
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Mixed effects modelling
Number of subjects: 115
Study: 36521888

Group type: EXPERIMENTAL
Intervention: Personalised StayFine app plus monitoring
Number of subjects: 254

Group type: COMPARATOR
Intervention: Monitoring only
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: StayFine modules
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Time to relapse (primary outcome)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Symptoms of depression and anxiety (secondary outcome)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Number and duration of relapses (secondary outcome)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Global functioning (secondary outcome)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Quality of life (secondary outcome)
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Mediators and moderators
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Monitoring and wearable outcomes (exploratory endpoints)
Number of subjects: 254
Study: 36521957

Group type: EXPERIMENTAL
Intervention: Government funding through balance allocation
Number of subjects: 660565

Group type: EXPERIMENTAL
Intervention: Financial problems that interrupted routine service delivery
Number of subjects: 660565

Group type: EXPERIMENTAL
Intervention: Setting performance-based bonus
Number of subjects: 660565

Group type: EXPERIMENTAL
Intervention: Basic salary defined by number of patient visits
Number of subjects: 660565

Group type: EXPERIMENTAL
Intervention: Using electronic referrals
Number of subjects: 660565

Group type: EXPERIMENTAL
Intervention: Implementing family physician contract services
Number of subjects: 660565

Group type: EXPERIMENTAL
Intervention: Proportion of physicians who are formally licensed
Number of subjects: 660565
Study: 36522265

Group type: EXPERIMENTAL
Intervention: Mixed V114/PCV13 regimen
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Toddler dose of V114
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: Mixed regimens with at least one infant dose plus toddler dose of V114
Number of subjects: 900

Group type: EXPERIMENTAL
Intervention: V114
Number of subjects: 900

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 900
Study: 36522279

Group type: EXPERIMENTAL
Intervention: Biodynamic drug response classifier (4-level classifier)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Biodynamic scoring
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-of-care cytotoxins (gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin)
Number of subjects: 30
Study: 36522365

Group type: EXPERIMENTAL
Intervention: Mogamulizumab (anti-CCR4 monoclonal antibody)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trametinib
Number of subjects: 0
Study: 36522418

Group type: EXPERIMENTAL
Intervention: Ultrasound (US) assessment of quadriceps femoris (QF) muscle architecture
Number of subjects: 70
Study: 36522434

Group type: EXPERIMENTAL
Intervention: Dermal graft (DG)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Split-thickness skin graft (STSG)
Number of subjects: 21
Study: 36522433

Group type: EXPERIMENTAL
Intervention: Driving pressure-guided ventilation with PEEP of 5 cm H2O
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36522453

Group type: EXPERIMENTAL
Intervention: Entropy-based EEG biomarkers of consciousness
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spectral EEG features
Number of subjects: 0
Study: 36522606

Group type: EXPERIMENTAL
Intervention: 10 mg dapagliflozin daily
Number of subjects: 6263

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study: 36522658

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 5
Study: 36522680

Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 33

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 33
Study: 36522698

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (experimental arm of the Covidicus trial)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recovery trial (control data)
Number of subjects: 0
Study: 36522767

Group type: EXPERIMENTAL
Intervention: Intravenous morphine plus paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine alone
Number of subjects: 0
Study: 36522772

Group type: EXPERIMENTAL
Intervention: Virtual parent-led peer support groups (vPLPSGs) for 6 months
Number of subjects: 44
Study: 36523131

Group type: EXPERIMENTAL
Intervention: Red blood cell exchange transfusion
Number of subjects: 3
Study: 36523236

Group type: EXPERIMENTAL
Intervention: Breaking Free Online (BFO) with group peer support
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Breaking Free Online (BFO) alone
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Breaking Free Online (BFO) with individual peer support
Number of subjects: 225

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 225
Study: 36523242

Group type: EXPERIMENTAL
Intervention: Integrated lifestyle intervention initiated at preconception and continuing throughout pregnancy and postpartum periods.
Number of subjects: 500
Study: 36523250

Group type: EXPERIMENTAL
Intervention: theory-derived intervention
Number of subjects: 440

Group type: COMPARATOR
Intervention: conventional health education
Number of subjects: 440
Study: 36523415

Group type: EXPERIMENTAL
Intervention: Bivalent SARS-CoV-2 recombinant protein vaccine with AS03-adjuvant (5 μg of D614 and 5 μg of B.1.351)
Number of subjects: 12924

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12924
Study: 36523440

Group type: EXPERIMENTAL
Intervention: Ischemic post-conditioning (0, 1, 2, 3, 4, and 5 min × 4 cycles)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Mechanical thrombectomy
Number of subjects: 3
Study: 36523553

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 36523754

Group type: EXPERIMENTAL
Intervention: Physiological monitoring while watching a disturbing video (group with ASD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Physiological monitoring while watching a relaxing video (group with ASD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Monitoring of 10 participants with ASD for 7 days to predict challenging behaviors (CBs)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Proof of concept (POC) testing of the developed system on one participant with ASD and CB
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Focus group feedback on the developed system
Number of subjects: 40
Study: 36524116

Group type: EXPERIMENTAL
Intervention: CD38-directed CAR-T cell therapy
Number of subjects: 2
Study: 36524126

Group type: EXPERIMENTAL
Intervention: Bivalent booster vaccination
Number of subjects: 0
Study: 36524254

Group type: EXPERIMENTAL
Intervention: 6-week gross motor intervention program
Number of subjects: 17
Study: 36524387

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 36524472

Group type: EXPERIMENTAL
Intervention: Circulating PAGln levels
Number of subjects: 4085

Group type: EXPERIMENTAL
Intervention: PAGln and phenylacetylglycine
Number of subjects: 4085
Study: 36524474

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study: 36524476

Group type: EXPERIMENTAL
Intervention: Diabetes present (109 patients)
Number of subjects: 898
Study: 36524539

Group type: EXPERIMENTAL
Intervention: Weight management medications (specific medications not detailed)
Number of subjects: 0
Study: 36524557

Group type: EXPERIMENTAL
Intervention: First-trimester HbA1c level of 6.5% (48 mmol/mol) or more excluded from the study.
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Higher HbA1c and random plasma glucose values in women who developed GDM.
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Combination of maternal characteristics (age, BMI, history of GDM, family history of diabetes) with HbA1c and random plasma glucose.
Number of subjects: 785
Study: 36524810

Group type: EXPERIMENTAL
Intervention: Placebo treatment (inert pill)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment arm
Number of subjects: 0
Study: 36524980

Group type: EXPERIMENTAL
Intervention: Asciminib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Investigator-selected TKI
Number of subjects: 0
Study: 36525069

Group type: COMPARATOR
Intervention: Pilates core stability exercises program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pilates core stability exercises program plus HUMAC balance program
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pilates core stability exercises program plus coordination exercises of BOT-2
Number of subjects: 60
Study: 36525080

Group type: EXPERIMENTAL
Intervention: Social Life outside work
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Physical Fitness
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Cognitive Functions
Number of subjects: 483
Study: 36525140

Group type: EXPERIMENTAL
Intervention: Eplontersen (ION-682884), a ligand-conjugated antisense oligonucleotide designed to degrade hepatic TTR mRNA.
Number of subjects: 168
Study: 36525147

Group type: EXPERIMENTAL
Intervention: Character strengths-based intervention (CSI)
Number of subjects: 0